Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2002 1
2003 1
2004 4
2005 1
2008 4
2009 2
2010 4
2011 5
2012 5
2013 2
2014 5
2015 9
2016 4
2017 10
2018 8
2019 2
2020 9
2021 3
2022 1
2023 7
2024 3

Text availability

Article attribute

Article type

Publication date

Search Results

79 results

Results by year

Filters applied: . Clear all
Page 1
Functional Precision Medicine Successfully Guides Therapeutic Regimen of 'Cancer of Unknown Primary' Later Classified as Triple-Negative Breast Cancer: A Case Report.
Ruhe L, Heibl S, Czompo M, Haybaeck J, Loskutov J, Regenbrecht MJ, Thaler J, Wedeken L, Alexander Regenbrecht CR. Ruhe L, et al. Among authors: thaler j. Case Rep Oncol. 2024 Mar 27;17(1):490-496. doi: 10.1159/000538137. eCollection 2024 Jan-Dec. Case Rep Oncol. 2024. PMID: 38545086 Free PMC article.
Quality of life, effectiveness, and safety of aflibercept plus FOLFIRI in older patients with metastatic colorectal cancer: An analysis of the prospective QoLiTrap study.
Piringer G, Thaler J, Anchisi S, Geffriaud-Ricouard C, Gueldner M, Scholten F, Derigs HG, Bohanes P, Grünberger B, Schwarz L, von Moos R, Hofheinz RD. Piringer G, et al. Among authors: thaler j. J Geriatr Oncol. 2023 Nov;14(8):101638. doi: 10.1016/j.jgo.2023.101638. Epub 2023 Sep 28. J Geriatr Oncol. 2023. PMID: 37776611
LM02 trial Perioperative treatment with panitumumab and FOLFIRI in patients with wild-type RAS, potentially resectable colorectal cancer liver metastases-a phase II study.
Piringer G, Gruenberger T, Thaler J, Kührer I, Kaczirek K, Längle F, Viragos-Toth I, Amann A, Eisterer W, Függer R, Andel J, Pichler A, Stift J, Sölkner L, Gnant M, Öfner D. Piringer G, et al. Among authors: thaler j. Front Oncol. 2023 Aug 9;13:1231600. doi: 10.3389/fonc.2023.1231600. eCollection 2023. Front Oncol. 2023. PMID: 37621684 Free PMC article.
Ongoing complete response after treatment cessation with dabrafenib, trametinib, and cetuximab as third-line treatment in a patient with advanced BRAFV600E mutated, microsatellite-stable colon cancer: A case report and literature review.
Piringer G, Decker J, Trommet V, Kühr T, Heibl S, Dörfler K, Thaler J. Piringer G, et al. Among authors: thaler j. Front Oncol. 2023 May 5;13:1166545. doi: 10.3389/fonc.2023.1166545. eCollection 2023. Front Oncol. 2023. PMID: 37213293 Free PMC article.
Real-World Evaluation of Quality of Life, Effectiveness, and Safety of Aflibercept Plus FOLFIRI in Patients with Metastatic Colorectal Cancer: The Prospective QoLiTrap Study.
Hofheinz RD, Anchisi S, Grünberger B, Derigs HG, Zahn MO, Geffriaud-Ricouard C, Gueldner M, Windemuth-Kieselbach C, Pederiva S, Bohanes P, Scholten F, Piringer G, Thaler J, von Moos R. Hofheinz RD, et al. Among authors: thaler j. Cancers (Basel). 2022 Jul 20;14(14):3522. doi: 10.3390/cancers14143522. Cancers (Basel). 2022. PMID: 35884583 Free PMC article.
79 results